3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
5
Recruiting
3
Terminated
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
23
Venous Thromboembolism
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Melanoma
1
Liposarcoma
1
Leiomyosarcoma
1
HR+HER2- Advanced Breast Cancer
1
Glioblastoma
1
Endometrial Neoplasms
1
EGFR-mutant Non-small Cell Lung Cancer
1
Cystadenocarcinoma, Serous
1
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
1
Colorectal Neoplasms
1
Cardiovascular Diseases
1
Carcinoma, Non-Small-Cell Lung
1
Breast Diseases
1
Anatomic Stage II Breast Cancer AJCC v8
1
Interventions
pembrolizumab
25
Cyclophosphamide
20
Nivolumab
13
Doxorubicin
13
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Exercise
9
atezolizumab
8
Vincristine
8
Rituximab
8
Radiotherapy
8
Prednisone
8
Dexamethasone
8
Bevacizumab
8
venetoclax
7
fludarabine
7
Pemetrexed
7
Fluorouracil
7
Docetaxel
7
Blood Specimen Collection
7
lenvatinib
6
dostarlimab
6
cemiplimab
6
budigalimab
6
Oxaliplatin
6
Cisplatin
6
durvalumab
5
Leucovorin
5
Lenalidomide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasms
×
ribociclib
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled